A Phase 2 interventional study of ruxolitinib in Thalassemia Major, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in beta-Thalassemia by Novartis — none open to participants now, none under way, none of them phase 3. beta-Thalassemia · Novartis.
Among the 11 studies in beta-Thalassemia by Novartis, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 2, and was the 11th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →None of the 11 studies in beta-Thalassemia by Novartis is open now. The open studies under beta-Thalassemia, anywhere →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3 · Phase 4 4
First in 2003; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 166 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in beta-Thalassemia by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with severe thalassemia (thalassemia major) present with severe anemia that required life-long transfusion therapy, spleen enlargement that led to increased transfusion requirement, and other serious complications as early death, growth retardation, bone deformations and iron overload due to blood transfusions. Splenectomy can significantly reduce transfusion requirement in thalassemia patients, but it is associated with an increased risk of serious complications such as sepsis and thrombosis. Preliminary preclinical and clinical data suggested that JAK2 inhibition, by reducing spleen size, could improve hemoglobin levels, thereby eliminating the need for splenectomy and reducing transfusion requirement and related iron overload.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Regularly transfused adult patients with thalassemia and spleen enlargement.
Drug: ruxolitinib
Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
Also known as: INC424
Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC)
Change of RBC transfusion requirement measured as percent change of the hematocrit-adjusted volume of transfused RBC and observed during within on-treatment interval (any time-points of RBC transfusion between week 6 and week 30 driven by the individual patient's need) compared to baseline (defined by pre-treatment interval between Week - 24 to start of treatment).
Time frame: week 6 to week 30 interval
Percentage Change in Spleen Volume (cm3)
Change of spleen volume from baseline at week 12 and week 30 as measured by magnetic imaging resonance (MRI) or computed tomography (CT).
Time frame: baseline, week 12, week 30
Percentage Change in Mean Pre-transfusion Hemoglobin by 6 Week Time Intervals
Change from baseline in pre-transfusion hemoglobin levels
Time frame: baseline, weeks 0 - 30
Percentage Change in Spleen Length (cm) Below the Left Coastal Margin
Change of spleen length from baseline over time measured by palpitation by time
Time frame: baseline, weeks 1,2,3,4,6,12,18,24,30
Pharmacokinetics (PK) Parameter of Cmin
C min of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 15 (Week 2), and Day 85 (Week 12). Cmin was collected immediately prior to dosing. n= number of patients with valid PK samples as per definition of the PK analysis set.
Time frame: week 2, week 12
Pharmacokinetics (PK) Parameter of Cmax
Cmax (1h) of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 1, Week 2, and Week 12. Cmax was collected within a +/- 1 hour post dose. n= number of patients with valid PK samples as per definition of the PK analysis set.
Time frame: Day 1, Week 2 (Day 15), Week 12 (Day 85)
| Milestone | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Started | 30 |
| Discontinued treatment prior to week 30 | 4 |
| Entered extension phase | 18 |
| Completed | 26 |
| Not completed | 4 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Patients/guardian decision | 1 |
Change of RBC transfusion requirement measured as percent change of the hematocrit-adjusted volume of transfused RBC and observed during within on-treatment interval (any time-points of RBC transfusion between week 6 and week 30 driven by the individual patient's need) compared to baseline (defined by pre-treatment interval between Week - 24 to start of treatment).
| % change of hematocrit-adjusted volume | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) | -5.934 ± 22.1681 |
Change of spleen volume from baseline at week 12 and week 30 as measured by magnetic imaging resonance (MRI) or computed tomography (CT).
| percentage change | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| % change from baseline at Week 12 | -19.733 ± 16.0539 |
| % change from baseline at Week 30 | -26.829 ± 16.6936 |
Change from baseline in pre-transfusion hemoglobin levels
| percentage change of hemoglobin levels | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Weeks 0 - 6 ) | 0.43 ± 10.135 |
| Weeks 6 - 12 | 2.87 ± 10.555 |
| Weeks 12 - 18 | 2.78 ± 11.081 |
| Weeks 18 - 24 | -0.56 ± 9.760 |
| Weeks 24 - 30 | 0.06 ± 14.321 |
Change of spleen length from baseline over time measured by palpitation by time
| percentage change in spleen length | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Week 1 | -11.19 ± 15.376 |
| Week 2 | -22.11 ± 23.604 |
| Week 3 | -25.01 ± 24.178 |
| Week 4 | -26.94 ± 25.343 |
| Week 6 | -33.85 ± 25.251 |
| Week 12 | -49.29 ± 26.792 |
| Week 18 | -56.32 ± 29.994 |
| Week 24 | -56.93 ± 29.552 |
| Week 30 | -57.40 ± 36.970 |
C min of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 15 (Week 2), and Day 85 (Week 12). Cmin was collected immediately prior to dosing. n= number of patients with valid PK samples as per definition of the PK analysis set.
| ng/mL | 10 mg Bid | 15mg Bid | 20mg Bid |
|---|---|---|---|
| Week 2 (Day 15) | 7.5800 ± 7.57959 | NA ± NA | NA ± NA |
| Week 12 (Day 85) | 9.1300 ± 7.61039 | 18.5400 ± 23.99940 | 20.2300 ± 25.98617 |
Cmax (1h) of INC424 by actual dose administered from 10mg bid to 20mg bid. Plasma PK samples were collected at Day 1, Week 2, and Week 12. Cmax was collected within a +/- 1 hour post dose. n= number of patients with valid PK samples as per definition of the PK analysis set.
| ng/mL | 5mg Bid | 10mg Bid | 15mg Bid | 20mg Bid |
|---|---|---|---|---|
| Day 1 | 58.2000 ± 0.00 | 126.8000 ± 58.70337 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 2 | 56.7000 ± 0.00 | 125.400 ± 40.61805 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 12 | 0.00 ± 0.00 | 107.2100 ± 50.07525 | 245.6900 ± 50.00362 | 185.0000 ± 97.58074 |
Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INC424 (Ruxolitinib) - Study Treatment | — | 6/30 (20%) | 23/30 (76.7%) |
| Event | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| PneumoniaInfections and infestations | 2/30 |
| AnaemiaBlood and lymphatic system disorders | 1/30 |
| NauseaGastrointestinal disorders | 1/30 |
| VomitingGastrointestinal disorders | 1/30 |
| PyrexiaGeneral disorders | 1/30 |
| Drug-induced liver injuryHepatobiliary disorders | 1/30 |
| Pneumonia viralInfections and infestations | 1/30 |
| Event | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/30 |
| Abdominal pain upperGastrointestinal disorders | 5/30 |
| DiarrhoeaGastrointestinal disorders | 5/30 |
| NauseaGastrointestinal disorders | 5/30 |
| Weight increasedInvestigations | 5/30 |
| AnaemiaBlood and lymphatic system disorders | 4/30 |
| Alanine aminotransferase increasedInvestigations | 4/30 |
| FatigueGeneral disorders | 3/30 |
| GastroenteritisInfections and infestations | 3/30 |
| NasopharyngitisInfections and infestations | 3/30 |
| Age, Continuous(years) | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Mean | 25.9 ± 6.83 |
| Sex: Female, Male(Participants) | INC424 (Ruxolitinib) - Study Treatment |
|---|---|
| Female | 12 |
| Male | 18 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from May 2014 to primary completion in Apr 2016, 22 months.
Results were first posted in Jun 2017, 1 year 2 months after primary completion.
Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib